Overview

ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV

Status:
Completed

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the effectiveness of an optimized anti HCV treatment (360μg per week of PegIFN-alpha2a + 18mg/kg/j of Ribavirin for 6 months.

Phase:

Phase 2

Details

Lead Sponsor:

ANRS, Emerging Infectious Diseases
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)

Collaborator:

Roche Pharma AG

Treatments:

Hepatitis C Antibodies
Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2a
Ribavirin